Share This Page
Drug Price Trends for NEOMYC-BACIT-POLYMIX EYE OINT
✉ Email this page to a colleague

Average Pharmacy Cost for NEOMYC-BACIT-POLYMIX EYE OINT
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
NEOMYC-BACIT-POLYMIX EYE OINT | 16571-0754-53 | 4.87931 | GM | 2025-05-21 |
NEOMYC-BACIT-POLYMIX EYE OINT | 24208-0780-55 | 4.87931 | GM | 2025-05-21 |
NEOMYC-BACIT-POLYMIX EYE OINT | 16571-0754-53 | 4.99640 | GM | 2025-04-23 |
NEOMYC-BACIT-POLYMIX EYE OINT | 24208-0780-55 | 4.99640 | GM | 2025-04-23 |
NEOMYC-BACIT-POLYMIX EYE OINT | 16571-0754-53 | 5.01756 | GM | 2025-03-19 |
NEOMYC-BACIT-POLYMIX EYE OINT | 24208-0780-55 | 5.01756 | GM | 2025-03-19 |
NEOMYC-BACIT-POLYMIX EYE OINT | 16571-0754-53 | 5.06040 | GM | 2025-02-19 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Neomycin, Polymyxin B, Bacitracin Ophthalmic Ointment: Market Analysis and Price Projections
Introduction
Neomycin, Polymyxin B, and Bacitracin ophthalmic ointment is a widely used antimicrobial agent for the treatment of superficial infections of the external eye and its adnexa. This article delves into the market analysis, price projections, and other relevant aspects of this medication.
Market Overview
The global eye drops and lubricants market, which includes ophthalmic ointments like Neomycin, Polymyxin B, and Bacitracin, is experiencing significant growth. As of 2017, the market size was $15,587 million and is projected to reach $22,625 million by 2025, growing at a CAGR of 4.7% from 2018 to 2025[3].
Segment Analysis
The ophthalmic anti-infectives segment, which includes this ointment, is part of a broader market that includes antibiotics, hormones, artificial tears, and other types of eye drops. The demand for ophthalmic anti-infectives is driven by the increasing prevalence of ophthalmic disorders such as conjunctivitis, keratitis, and blepharitis[3].
Indications and Usage
Neomycin, Polymyxin B, and Bacitracin ophthalmic ointment is specifically indicated for the topical treatment of superficial infections of the external eye and its adnexa, including conditions like conjunctivitis, keratitis, keratoconjunctivitis, blepharitis, and blepharoconjunctivitis. The broad-spectrum antibacterial action provided by the combination of neomycin, polymyxin B, and bacitracin makes it effective against a wide range of gram-positive and gram-negative organisms[1][5].
Pharmacological Class and Mechanism
This ointment belongs to the class of ophthalmic anti-infectives and works through the combined antibacterial actions of its components:
- Neomycin: Inhibits protein synthesis by binding to ribosomal RNA.
- Polymyxin B: Increases bacterial cell membrane permeability.
- Bacitracin: Interferes with bacterial cell wall synthesis[1][5].
Pricing and Availability
The cost of Neomycin, Polymyxin B, and Bacitracin ophthalmic ointment can vary depending on the pharmacy and location. On average, a 3.5-gram supply of the ointment costs around $28 for cash-paying customers. This price is based on using discount cards accepted at most U.S. pharmacies[2].
Patient Assistance Programs
While there are no specific patient assistance programs available for this medication, healthcare providers may have information on other programs that could help reduce the cost for individuals with low income or those who are uninsured/under-insured[2].
Market Trends and Projections
Regional Analysis
The eye drops and lubricants market, including ophthalmic ointments, is analyzed across various regions such as North America, Europe, Asia-Pacific, and LAMEA. North America holds the highest market share due to the high prevalence of ophthalmic disorders like glaucoma and cataracts. However, the Asia-Pacific region is expected to emerge as a lucrative market due to rapid healthcare infrastructure development and increasing incidence of ophthalmic disorders[3].
Growth Drivers
The market growth is driven by several factors:
- Increasing Prevalence of Ophthalmic Disorders: Conditions such as dry eye syndrome, conjunctivitis, and other infections are becoming more common.
- Advancements in Drug Discovery and Development: New formulations and improved efficacy of ophthalmic medications are boosting market growth.
- Demographic Changes: Aging populations and changes in lifestyle contribute to the rise in ophthalmic disorders[3].
Challenges
Despite the growth, the market faces challenges such as:
- Risk of Side Effects: Ophthalmic medications, including this ointment, can have side effects that may deter some users.
- Stringent Regulations: Regulatory hurdles can slow down the approval and launch of new products[3].
Key Takeaways
- Market Growth: The global eye drops and lubricants market, including ophthalmic ointments, is projected to grow significantly.
- Pricing: The cost of Neomycin, Polymyxin B, and Bacitracin ophthalmic ointment is around $28 for a 3.5-gram supply.
- Indications: The ointment is used for treating superficial infections of the external eye and its adnexa.
- Pharmacological Action: The combination of neomycin, polymyxin B, and bacitracin provides broad-spectrum antibacterial action.
- Regional Trends: North America leads the market, but Asia-Pacific is emerging as a significant growth area.
FAQs
What are the common indications for Neomycin, Polymyxin B, and Bacitracin ophthalmic ointment?
This ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa, including conjunctivitis, keratitis, keratoconjunctivitis, blepharitis, and blepharoconjunctivitis[1][5].
How does Neomycin, Polymyxin B, and Bacitracin ophthalmic ointment work?
The ointment works through the combined antibacterial actions of neomycin, polymyxin B, and bacitracin, which inhibit protein synthesis, increase cell membrane permeability, and interfere with cell wall synthesis, respectively[1][5].
What is the average cost of Neomycin, Polymyxin B, and Bacitracin ophthalmic ointment?
The average cost is around $28 for a 3.5-gram supply, depending on the pharmacy and location[2].
Are there any patient assistance programs available for this medication?
There are no specific patient assistance programs available for this medication, but healthcare providers may have information on other programs that could help reduce the cost[2].
What are the key drivers of the market growth for ophthalmic anti-infectives?
The market growth is driven by the increasing prevalence of ophthalmic disorders, advancements in drug discovery and development, and demographic changes[3].
What regions are expected to show significant growth in the ophthalmic anti-infectives market?
North America currently holds the highest market share, but the Asia-Pacific region is expected to emerge as a lucrative market due to rapid healthcare infrastructure development and increasing incidence of ophthalmic disorders[3].
Sources
- Drugs.com: Neomycin, Polymyxin B, Bacitracin Ophthalmic Ointment.
- Drugs.com: Bacitracin / neomycin / polymyxin b ophthalmic Prices.
- Allied Market Research: Eye Drops and Lubricants Market Size, Share & Industry Analysis.
- eMPR.com: Polymyxin B/Bacitracin/Neomycin Oph Oint.
- DailyMed: Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP.
More… ↓